ANTHONY DUK: Open Payments
NPI 1154439131 · REDLANDS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,032 in 207 payments from 19 companies in 2025. Trend: 2023 $2,267 · 2024 $2,307 · 2025 $4,032
Food & beverage: $4,026Education: $5
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 31 | $599 |
| ABBVIE INC. | 31 | $598 |
| Teva Pharmaceuticals USA, Inc. | 27 | $521 |
| Alkermes, Inc. | 22 | $472 |
| E.R. Squibb & Sons, L.L.C. | 25 | $412 |
| Neurocrine BioSciences, Inc. | 17 | $395 |
| Janssen Pharmaceuticals, Inc | 18 | $293 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $180 |
| Lundbeck LLC | 13 | $143 |
| Almatica Pharma LLC | 7 | $140 |
Products named: VRAYLAR, REXULTI, ARISTADA, INGREZZA, AUSTEDO XR, COBENFY, INVEGA SUSTENNA, CAPLYTA.
Industry payments across CA — which companies pay providers there.
